Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine


Adaikkalam Vellaichamy, Ph.D. 

Adaikkalam Vellaichamy, Ph.D.

Adaikkalam Vellaichamy, Ph.D.

Assistant Member
The Department of Nanomedicine
Houston Methodist Research Institute
Co-Director, Proteomics Core 
E-mail: avellaichamy@houstonmethodist.org
Phone: 713-441-7361


B.Sc.   Bharathidasan University, India (Biology and Chemistry)
M.Sc.   Bharathidasan University, India (Biology)
M.Tech.   Anna University, India (Biotechnology)
Ph.D.   National University of Singapore (Molecular Biology)

Postdoctoral Training

Genome Institute of Singapore, Singapore (Mass spectrometry, Medical Proteomics, Breast Cancer)

Michigan Center for Translational Pathology, University of Michigan, MI (Proteomics, Integrated Omics of Prostate Cancer)

Institute for Genomic Biology, University of Illinois at Urbana-Champaign, IL (High-resolution Mass spectrometry, Top-down Proteomics)



Dr. Vellaichamy obtained his master's degrees in science and technology in India, and earned his Ph.D from the National University of Singapore in 2003. He completed two years of postdoctoral training at the Genome Institute of Singapore in the area of mass-spectrometry based medical proteomics. He then joined the Department of Pathology at the University of Michigan in Ann Arbor to pursue his postdoctoral research in the area of cancer proteomics. With a major focus on mass spectrometry based proteomics, his research involved integrated omics approaches to understand the molecular mechanisms in prostate cancer development.

In 2008, Dr. Vellaichamy joined the Institute for Genomic Biology at the University of Illinois at Urbana-Champaign as an Institute Research Fellow . He played a lead role in the development of a robust mass spectrometry analysis strategy to perform on-line LC-MS of intact, high-molecular-weight proteins. In Nov. 2010, Dr. Vellaichamy was appointed as Assistant Member of Houston Methodist Research Institute and joined the Department of Nanomedicine. He is also the Co-Director of the Proteomics core facility.

Description of Research

Dr. Vellaichamy's research focuses on understanding the development and progression of cancer and other (cardiovascular, neurodegenerative and metabolic) diseases using state of the art proteomics technologies. One of his research projects is the development of Nanoporous Silica Chip-based enrichment of the low molecular weight proteome from complex biological samples. A second project is the identification of novel biomarkers using high resolution MALDI and ESI-mass-spectrometry. The Research Institute mass-spectrometry core and the collaborative translational research environment synergizes with Dr. Vellaichamy's plans to interrogate and delineate disease-specific protein networks using bottom-up and top-down proteomics strategies.

Major Areas of Research

Proteomics, high-resolution mass spectrometry, nano-chips, cancer, biomarkers, diagnostics

Recent Publications

Ateeq B, Vellaichamy A, Tomlins SA, Wang R, Cao Q, Lonigro RJ, Pienta KJ, Varambally S (2012). Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. Prostate. 2012 Mar 13. doi: 10.1002/pros.22509.

Tran JC, Zamdborg L, Ahlf DR, Lee JE, Catherman AD, Durbin KR, Tipton JD, Vellaichamy A, Kellie JF, Li M, Wu C, Sweet SM, Early BP, Siuti N, LeDuc RD, Compton PD, Thomas PM, Kelleher NL (2011). Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature  480(7376):254-258.

Vellaichamy A, Tran JC, Catherman AD, Lee JE, Kellie JF, Sweet SM, Zamdborg L, Thomas PM, Ahlf DR, Durbin KR, Valaskovic GA, and Kelleher NL (2010). Size-Sorting Combined with Improved Nanocapillary-LC-MS for Identification of Intact Proteins up to 80 kDa. Anal Chem. 82(4):1234-1244.

Vellaichamy A, Lin CY, Aye TT, Kunde KR, Nesvizhskii AI, Liu ET, and Sze SK (2010). A Chloroform-Assisted Protein Isolation Method Followed by Capillary NanoLC-MS Identify Estrogen-Regulated Proteins from MCF7 Cells. J Proteomics Bioinform. 3: 212-220.

Vellaichamy A, Dezso Z, JeBailey L, Chinnaiyan AM, Sreekumar A, Nesvizhskii A, Omenn GS, and Bugrim A (2010). Networking genes with proteins: finding relations between proteomic and gene expression datasets using topology of the global interaction network. PLoS One. 5(6):e10936.

Kellie JF, Tran JC, Lee JE, Ahlf DR, Thomas HM, Ntai I, Catherman AD, Durbin KR, Zamdborg L, Vellaichamy A, Thomas PM, and Kelleher NL (2010). The Emerging Process of Top-Down Mass Spectrometry- Biomarkers, Protein-Therapeutics, and Achieving High Throughput. Mol Biosyst. 6: 1-8.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang GX, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM (2010). An Integrated Network of Androgen Receptor and TMPRSS2-ERG Gene Fusion in Prostate Cancer Progression. Cancer Cell. 17(5):443-454.

Vellaichamy A, Sreekumar A, Rajendiran T, Yu J, Varambally S, Li Y, Omenn GS, Chinnaiyan AM, and Nesvizhskii AI (2009). Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases. PLoS One. 4(9):e7075.

Lee JE, Kellie JF, Tran JC, Tipton JD, Catherman AC, Thomas HM, Ahlf DR, Durbin KR, Vellaichamy A, Ntai I, Hendrickson CL, Emmett MR, Marshall AG, and Kelleher NL (2009). A Robust 2-Dimensional Separation for Top-Down Tandem Mass Spectrometry of the Low Mass Proteome. J Am Soc Mass Spectrom. 20(12):2183-2191.

Woods Ignatoski KM, Grewal NK, Markwart SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME, Keller ET. (2008). Loss of Raf Kinase Inhibitory Protein (RKIP) induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys. 72:153-160.

Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, Gu W, Shen R, Ghosh D, Wright LM, Kladney RD, Kuefer R, Rubin MA, Fimmel CJ, Chinnaiyan AM. (2008) Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia. 10:1285-94.


Department of Nanomedicine
Proteomics Programmatic Core